Objective: To test the hypothesis that the effect of antithrombotic medications on the risk of intracerebral hemorrhage (ICH) varies according to the location of the hematoma.
Results: A total of 870 (313 lobar ICH, 557 deep ICH) subjects were included. Of these, 223 (25.6%) were taking antiplatelets and 77 (8.8%) OACs at the time of stroke. The odds of antiplatelet-related ICH increased with aging (odds ratio [OR] 1.05; 95% confidence interval [CI] 1.03-1.07) and hypertension (OR 1.86; 95% CI 1.22-2.85) but had no relation with the anatomical location of ICH. Conversely, lobar location of the hematoma was associated with the subgroup of OAC-related ICH (OR 1.70; 95% CI 1.03-2.81) when compared to the subgroup of patients taking no antithrombotic medications. Within the subgroup of patients taking OACs, international normalized ratio (INR) values were higher in those with lobar ICH as compared to those with deep ICH (2.8 6 1.1 vs 2.2 6 0.8; p 5 0.011). The proportion of patients with lobar hematoma increased with increasing intensity of anticoagulation, with a ;2-fold increased odds of lobar compared to deep ICH (odds 2.17; p 5 0.03) in those exposed to overanticoagulation (INR values .3.0).
Conclusions:
OACs, as opposed to antiplatelets, predispose to lobar location of brain hematomas according to a dose-response relationship. Neurology ® 2014;82:529-535 GLOSSARY BMI 5 body mass index; BP 5 blood pressure; CAA 5 cerebral amyloid angiopathy; CI 5 confidence interval; ICH 5 intracerebral hemorrhage; INR 5 international normalized ratio; MUCH-Italy 5 Multicenter Study on Cerebral Hemorrhage in Italy; OAC 5 oral anticoagulant.
Antithrombotic medications are a highly effective therapy for the prevention of thromboembolic strokes in common clinical situations. However, the increasing use of both antiplatelet and oral anticoagulant (OAC) agents in an aging population has been associated with an increased risk of intracerebral hemorrhage (ICH), [1] [2] [3] [4] with the annual incidence ranging from 0.02% to 0.47% in patients taking a single antiplatelet agent to 0.3%-0.6% in those on OAC therapy. 5, 6 The prevention of ICH in patients with antithrombotic medications is therefore critical, and the identification of risk factors for bleeding is an important practical issue. Data are needed to determine how specific markers may contribute to individualized risk prediction in order to make antithrombotics as safe and effective as possible. Several lines of evidence support the hypothesis that age-related disorders of cerebral small vessels are closely linked to this rare but devastating complication of antithrombotics use. In other terms, antithrombotic medications per se might not cause ICH if cerebral vessels are intact, but the presence of microangiopathy, rendering small vessels brittle and fragile, is a plausible causal or predisposing factor for bleeding. In this regard, sparse reports have suggested that cerebral amyloid angiopathy (CAA) may be a stronger predictor of antithrombotic-associated ICH than hypertensive microangiopathy, 7-10 but some recent observations have questioned this assumption. 11, 12 Thus, any specific relation has not yet been established. The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy) provides the opportunity to investigate this issue owing to its large sample size, the homogeneous demographic characteristics and clinical phenotype of the subjects included, and the standard diagnostic workup. Therefore, we aimed to evaluate whether 1) antithrombotic medications have differential influence on specific small cerebral vessel pathology, using hemorrhage location (deep vs lobar) to categorize the likely etiology, and 2) any doseeffect relationship of anticoagulation may further predispose to bleeding, in a cohort of Italian stroke patients with ICH.
METHODS Study group. MUCH-Italy is a countrywide network of neurologic centers aimed at recruiting patients with cerebral hemorrhage in the setting of a hospital-based, multicenter, observational study, as previously described. 13 For the purpose of the present analysis, we screened datasets from patients with acute ICH consecutively admitted to 4 hospitals between January 2002 and July 2011. Eligibility for study participation required neuroimaging (CT or MRI) confirmation of hemorrhagic stroke. Exclusion criteria included the presence of trauma, brain tumor, hemorrhagic transformation of a cerebral infarction, vascular malformation, or any other perceived cause of secondary ICH. ICH location was assigned based on admission CT scan by stroke neurologists at each participating center. ICH isolated to the cortex (with or without involvement of subcortical white matter) and cerebellar hematomas were defined as lobar ICH, while ICH selectively involving the thalamus, basal ganglia, or brainstem was defined as deep (nonlobar) ICH. Multiple concurrent bleeds involving deep and lobar territories were defined as mixed ICH and represented an exclusion criterion. Demographic and clinical information, as well as neuroimaging data, were collected prospectively and ascertained by neurologists in each center. International normalized ratio (INR) was determined in each patient at admission as part of routine laboratory testing.
Standard protocol approvals, registrations, and patient consents. The study was approved by relevant local authorities at each study site. Written informed consent was obtained from all patients (or next of kin).
Risk factor definition. Subjects were classified as current smokers if they were currently smoking one or more cigarettes per day on a regular basis. Hypertension was defined as systolic blood pressure (BP) .140 mm Hg or diastolic BP .90 mm Hg out of the acute phase or using pharmacologic treatment for hypertension. Hypercholesterolemia was considered as cholesterol .240 mg/dL out of the acute phase or using pharmacologic treatment to lower blood lipids. Diabetes was defined as fasting glucose levels .125 mg/dL out of the acute phase or current treatment with antidiabetic drugs. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters (kg/m 2 ) and subjects dichotomized into obese (BMI $30.0 kg/m 2 ) and nonobese (BMI ,30.0 kg/m 2 ). Based on daily alcohol consumption, subjects were dichotomized into excessive drinkers (.45 g of alcohol) and light to moderate drinkers/nondrinkers. We also collected information on atrial fibrillation (medical history or electrocardiographic findings at admission), atherosclerotic peripheral arterial disease (medical history), coronary artery disease (medical history of angina, myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty), history of previous stroke or TIA (based on clinical history), and pre-ICH medications (warfarin, aspirin or other antiplatelet agents, antihypertensive agents, oral hypoglycemic agents or insulin, and statins). 13 Data were obtained from interviews with patients, next of kin, or attending physicians or general practitioners.
Statistical analyses. Differences among the treatment groups
(ICHs unrelated to antithrombotic medications, antiplateletrelated ICHs, and OAC-related ICHs) were examined with the x 2 test, median test, and analysis of variance F test, when appropriate. Categorical (multinomial) logistic regression model was performed to examine the conditional effect of risk factors (hypertension, diabetes, hypercholesterolemia, smoking, alcohol consumption) and location of the hematoma (deep vs lobar) in the prediction of ICH subgroups, adjusted for age and sex (model 1). Since both CAA and hypertensive vasculopathy may be involved in the pathogenesis of cerebellar hemorrhages, 14 we conducted a separate analysis after exclusion of the cerebellar ICH cases from the study group, to minimize their potentially confounding effect (model 2 No patient was on treatment with other antithrombotic agents (i.e., heparin) before admission. The characteristics of the study group are summarized in table 1, stratified by antithrombotic medications. Overall, patients treated with antithrombotics were older and more frequently female and had a higher prevalence of risk factors (in particular, hypertension) and comorbidities (previous brain ischemia, ischemic heart disease, and atrial fibrillation) than patients who were not on treatment.
The majority of antiplatelet users were on treatment with aspirin (n 5 207, 90.8%; ticlopidine, n 5 17, 7.5%; clopidogrel, n 5 3, 1.3%; aspirin plus dipyridamole, n 5 1, 0.4%). Among OAC users, 7 As summarized in table 2, aging had a similar effect on increasing the risk of disease in the group of antiplatelet-related ICH (OR 1.05; 95% CI 1.03-1.07) as well as in that of OAC-related ICH (OR 1.06; 95% CI 1.03-1.09) when compared to the reference group of patients who were taking no antithrombotic medications at the time of stroke occurrence. In addition, we observed an increase in the risk of ICH with hypertension, which was significant only in the subgroup of patients with antiplatelet-related ICH (OR 1.86; 95% CI 1.22-2.85). None of the other traditional vascular risk factors had any independent influence on the risk of antithrombotic-related ICH. Lobar location of the hematoma was associated with the subgroup of OAC-related ICH (OR 1.70; 95% CI 1.03-2.81), as opposed to what was observed for deep ICH, while hemorrhage location had no significant association with the subgroup of antiplateletrelated ICH (model 1). Results remained substantially unchanged when data were reanalyzed after removing the subgroup of patients with cerebellar hemorrhages (model 2, not shown). Within the subgroup of OAC-related ICH, the frequency of ICH increased in both deep and lobar brain regions with increasing INR values up to 3.0, with no difference between the 2 . DISCUSSION The precise contribution of antithrombotic medications to the location of ICH has not yet been determined. Our study, involving a large cohort of patients with ICH, indicates that antiplatelet agents have a negligible influence on the site of bleeding, their effect probably being overcome by that of other predisposing conditions, such as aging and hypertension, while, conversely, the use of OACs predisposes to lobar location of brain hematomas. These findings confirm and extend those of previous studies on the relation between antithrombotic medications and hemorrhagic stroke and add further data on the question of whether the contribution of these agents, especially OACs, to cerebral bleeding might vary by anatomical location. First, they confirm that ICH is common in patients treated with antithrombotic drugs, independent of the anatomical location of bleeding. Furthermore, in our series like in prior studies, 8, 15, 16 a relevant proportion of ICH among those on OACs occurred when the INR values were in the therapeutic range. Second, they support previous observations that OAC-related ICHs occur with a slightly more frequent lobar location. [7] [8] [9] [10] However, data on the impact of specific small-vessel arteriopathies on OAC-related ICH are scarce, mainly derived from studies including small case series, sometimes recording individual history of OAC use without taking into consideration the intensity of anticoagulation, 7 including patients receiving heparin at the time of stroke, 8, 11 or aimed at addressing different issues, 8, 9, 11 with only a few notable exceptions. 10, 12 In this regard, a novel finding from our data is the evidence of a direct dose-response relationship between OAC treatment and lobar ICH, as illustrated by the increasing number of patients in this subgroup as the INR values increase. We speculate that OACs affect CAA and hypertensive arteriolosclerosis equally when INR values are within the therapeutic range, but that they exert a differential impact on the 2 cerebral microangiopathies, with a greater effect on cortical-subcortical vessels, in case of excessive anticoagulation. As a consequence of this, there might be an individual threshold of INR values over which the influence of OACs on hematoma location becomes more evident. It remains unclear whether this is a causal association, or, more likely, the end result of a dynamic interplay among several conditions including the underlying bleeding-prone small-vessel disease, the direct effect of these agents on the clotting cascade, and other unknown factors. Though unproven, a number of histologic findings provide biologic support to this view. Arteriolar wall thinning, interposition of amyloid deposits between smooth muscle cells, dilated perivascular spaces, and microaneurysms are frequent findings in CAA involving lobar brain regions, whereas thickening of the vessel wall caused by lipohyalinosis in response to chronic hypertension is the pathologic marker of arteriolosclerosis in deep regions. It is likely that these abnormalities might render cortical-subcortical vessels more vulnerable to rupture and with less potential for tamponade compared to deep perforating arteries in the presence of excessive anticoagulation. 17, 18 In addition, evidence supporting a link between CAA and OAC-ICH includes the demonstration that the APOE e2 allele, a known genetic risk factor of CAA-related lobar ICH, 19, 20 is more common in warfarin-associated ICH than in control patients on warfarin without ICH, 8 and that individual cases of ICH following anticoagulation or coronary thrombolysis revealed advanced CAA on autopsy. 21, 22 Our findings are in apparent disagreement with those derived from the PITCH study by Dequatre-Ponchelle et al. 12 who found no influence of OACs on the anatomical distribution of ICH but a significant effect of these compounds on the volume of deep brain hematomas. This would support the conclusion that deep perforating arteries are more sensitive to anticoagulation than cortical-subcortical vessels. Such a discrepancy might be explained by the slightly different definition of deep and lobar ICH in the 2 studies, as well as by the potential biases in the measurement of hematoma volumes, as pointed out by the authors themselves, and, even more important, by the fact that regression models in the PITCH study did not include adjustment for hypertension. 12 Furthermore, because existing evidence suggests that both CAA and hypertension can be responsible for intracranial bleeding in the cerebellum, 14 analyses on the relation between risk factors and ICH location should consider cerebellar hemorrhages as a potential source of bias and take account of this. Several strengths of the present study should be noted, including the large number of participants, the homogeneous demographic characteristics and clinical phenotype of the cohort, and the standardized diagnostic workup and evaluation of risk factors. Some limitations also should be considered. First, because the MUCH-Italy is a hospitalbased study, the results might be susceptible to hospital referral selection bias. However, inaccurate capture of the incident cases is highly unlikely as all patients with acute cerebral hemorrhage in the geographic areas involved in the study are usually referred to the participating centers. Second, because of the relatively small numbers of subjects in specific subgroups, such as in the upper INR strata, some results should be viewed with caution. Third, recruitment time period was long, during which improvement in diagnostic facilities and preventive medications has occurred. In particular, because brain MRI was not part of the routine imaging protocol during the first years of the study, only a small proportion of patients have these data available. This precluded the inclusion of neuroradiologic markers that could be of interest, such as brain microbleeds, 23 in the final analysis. Fourth, we cannot theoretically exclude a classification bias in categorizing patients' medical history or the potential influence of other, undetected medical conditions (i.e., chronic kidney disease) on the results of the study.
In spite of these limitations, our findings provide evidence that OACs, as opposed to antiplatelet agents, increase the propensity to cerebral bleeding to a higher degree in lobar than in deep brain regions. This differential effect should be considered in future trials with new antithrombotic agents, as well as with any new molecules interfering with clot formation and, in clinical practice, when the potential benefits of OACs as regards stroke prevention are to be balanced against their bleeding risk. We hypothesize that a similar effect will be seen with novel OACs or with multiple antithrombotic therapies, but further dedicated studies are needed.
